0002001011-24-000079.txt : 20240830
0002001011-24-000079.hdr.sgml : 20240830
20240830205618
ACCESSION NUMBER: 0002001011-24-000079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240828
FILED AS OF DATE: 20240830
DATE AS OF CHANGE: 20240830
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reardon Andrew
CENTRAL INDEX KEY: 0001950232
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 241271633
MAIL ADDRESS:
STREET 1: C/O LIGAND PHARMACEUTICALS INCORPORATED
STREET 2: 3911 SORRENTO VALLEY BLVD, SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-08-28
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001950232
Reardon Andrew
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
0
1
0
0
CLO & Secretary
0
Common Stock
2024-08-28
4
M
0
1500
52.27
A
24034
D
Common Stock
2024-08-28
4
S
0
1500
106.3937
D
22534
D
Non-Qualified Stock Option (right to buy)
52.27
2024-08-28
4
M
0
1500
0.0
D
2032-08-01
Common Stock
1500
61444
D
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $106.3200 to $106.4700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
/s/ Andrew Reardon
2024-08-30